Earnings inflection analysis
Eli Lilly and Company (LLY) · 2026Q1 earnings call · 27 inflection points identified
Generated 08 August 2026 · this analysis is stored and reused, so repeat visits are served instantly from cache.
Full-year revenue guidance raised by $2 billion at both ends to $82-85 billion, reflecting stronger-than-expected underlying Mounjaro and Zepbound performance in Q1.
“We have increased the top and the bottom end of the revenue range by $2 billion and now expect full year revenue to be between $82 billion and $85 billion.”— Lucas Montarce, Chief Financial Officer
Non-GAAP EPS guidance raised by $2 at both ends to $35.50-$37, driven by higher expected revenue.
“we now expect non-GAAP earnings per share of $35.50 to $37, an increase of $2 to both the top and bottom”— Lucas Montarce, Chief Financial Officer
China revenue growth accelerated following Mounjaro's inclusion on the national reimbursement drug list for type 2 diabetes.
Per Lucas Montarce, Chief Financial Officer
Rest of World revenue more than doubled in constant currency as Mounjaro achieved rapid share gains in Latin America and Asia, a notably faster pace than other regions.
Per Lucas Montarce, Chief Financial Officer
U.S. price declined 7% (10% excluding a one-time rebate/discount estimate adjustment), reflecting new direct-to-patient pricing and negotiated government outcomes, a shift from prior pricing stability.
Per Lucas Montarce, Chief Financial Officer
Management described obesity/weight-loss pricing dynamics as distinct from typical pharma, with price reductions producing outsized, nonlinear volume expansion rather than the usual price-sensitivity tradeoff.
“pretty much every time we reduce pricing, we see a pretty large expansion”— David Ricks, Chair and CEO
In China, Lilly accepted a meaningful negotiated price cut for diabetes access, but volume gains far outstripped the price concession, shifting the net revenue effect positive despite lower price.
Per David Ricks, Chair and CEO
Zepbound prescription growth outpaced the overall incretin obesity market's 80%+ growth, driven by continued strength in the self-pay channel and steady commercial segment growth.
Per Lucas Montarce, Chief Financial Officer
Loss of Medicaid access in certain states newly weighed on Zepbound prescription growth, cutting Q1 growth by a high single-digit percentage.
Per Lucas Montarce, Chief Financial Officer
With Lilly already holding market leadership outside the U.S. since Q4 2025 and share above 53%, management signaled incremental share gains are getting harder and future growth will increasingly depend on patient activation rather than share capture.
“with share leadership already established, increased patient activation will be key to drive sustainable growth”— Patrik Jonsson, President, Lilly International
Despite generic semaglutide entering India, Mounjaro prescriptions are running about 10% higher than before the generic launch, as the dual agonist outperformed single agonists and generics stimulated overall market growth rather than eroding Lilly's volumes.
“Mounjaro prescriptions...are about 10% higher in recent weeks compared to the period prior to generic semaglutide”— Patrik Jonsson, President, Lilly International
Lilly launched Employer Connect, a new platform enabling employers to offer obesity medicines with transparent pricing and flexible plan design, with management citing encouraging early employer interest despite it being very early.
Per David Ricks, Chair and CEO
Foundayo regulatory reviews are ongoing in over 40 countries, with management now expecting an accelerated cadence of international launches as the company exits 2026 into 2027, representing a new scaling phase beyond the initial U.S. launch.
Per David Ricks, Chair and CEO
Foundayo (orforglipron) received FDA approval, marking the first time a new incretin medicine has launched with obesity as its first indication, introducing a new oral GLP-1 modality to the market.
“This is the first time a new incretin medicine has been launched with obesity as its indication first.”— David Ricks, Chair and CEO
Early Foundayo launch metrics show over 20,000 patients treated and 8,000+ prescribers within weeks, with 80% of prescriptions new-to-class and one-third of prescribers new to oral GLP-1s, indicating the launch is expanding rather than cannibalizing the market.
Per Livia Yuffa, President, Lilly USA & Global Customer Capabilities
New ACHIEVE I Phase III data added cardiovascular safety and a lower risk of all-cause death to Foundayo's clinical profile, a new dimension beyond prior A1c and weight-loss data, supporting the upcoming U.S. type 2 diabetes submission.
Per Daniel Skovronsky, Chief Scientific and Product Officer
Retatrutide's first Phase III trial in type 2 diabetes (TRANSCEND P2D-1) showed glycemic control comparable to tirzepatide while delivering additional weight loss, establishing a newly favorable clinical profile for the molecule.
Per Daniel Skovronsky, Chief Scientific and Product Officer
Pertibrutinib became the first medicine to outperform a venetoclax-containing control arm in a Phase III trial in the history of CLL drug development, strengthening its position as a potential foundational CLL therapy.
Per Daniel Skovronsky, Chief Scientific and Product Officer
Lurio's launch in metastatic renal cell cancer was encouraging in its first full quarter, achieving over 35% share of new patient starts, ahead of typical early-launch expectations.
Per Lucas Montarce, Chief Financial Officer
Gross margin declined roughly one percentage point year over year to 82.6%, driven primarily by lower net prices, reversing from margin stability in prior periods.
Per Lucas Montarce, Chief Financial Officer
Non-GAAP performance margin rose approximately seven percentage points year over year to 50%, driven by strong revenue growth outpacing expense growth.
Per Lucas Montarce, Chief Financial Officer
R&D expense growth accelerated to 28%, reflecting continued investment across a now-record 42 active Phase III programs.
Per Lucas Montarce, Chief Financial Officer
Marketing, selling and administrative expenses rose 19% as the company stepped up promotional investment specifically to support the Foundayo launch and other planned new product launches.
Per Lucas Montarce, Chief Financial Officer
Generic semaglutide's entry in India appears to be expanding the overall obesity market rather than eroding Mounjaro's position, with management noting dual agonists are outperforming single agonists in this new competitive setting.
Per Patrik Jonsson, President, Lilly International
Management identified negotiated government pricing outcomes, including the MFN package, as the primary driver of the Q1 U.S. price decline, a new policy-driven pressure on pricing versus prior periods.
Per David Ricks, Chair and CEO
CMS extended the Medicare GLP-1 bridge program through December 2027 after Part D plans did not opt in at the rate the government initially expected, providing new $50/month capped access for seniors sooner than a full Part D solution.
Per David Ricks, Chair and CEO
No significant change or new commentary noted.
No significant change or new commentary noted.
Lilly announced four new acquisitions in the quarter (Orna, Syntessa, Colonia, Ajax) plus Contessa, signaling a step-up in business development pace to expand pipeline breadth across immunology, neuroscience and oncology.
“We expect to remain active in business development to complement our internal portfolio, while maintaining the discipline to create shareholder value.”— David Ricks, Chair and CEO
No significant change or new commentary noted.
No significant change or new commentary noted.
This page is an AI-generated summary of management commentary from a public earnings call. It may contain errors or omissions, is not a substitute for the primary source, and is not investment advice.
Earnings data and call transcripts provided by Alpha Vantage.